Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

Description

This is a proof of concept observational study is to determine if there is correlation between Aβ plaques and vascular findings in the Retina versus brain ARIA.

Conditions

Mild Cognitive Impairment, Alzheimer Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a proof of concept observational study is to determine if there is correlation between Aβ plaques and vascular findings in the Retina versus brain ARIA.

Proof of Concept of the Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease

Condition
Mild Cognitive Impairment
Intervention / Treatment

-

Contacts and Locations

Sacramento

Sutter Health, Sacramento, California, United States, 95816

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Subjects must be eligible for and intend to receive LEQEMBI under standard of care treatment.
  • 2. Male and female subjects ages ≥50 years old.
  • 3. Must be willing to comply with protocol including pupillary dilation to a minimum of 3.5 mm to allow for ocular imaging.
  • 4. Patient or patient's legally authorized representative (LAR) (e.g., spouse or legal guardian) has the ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local patient privacy regulations.
  • 1. History of acute angle-closure glaucoma or allergic reaction to the protocol-specified ophthalmic medication for dilation of the pupils.
  • 2. Self-reported or diagnosed history of dense cataracts or other significant media opacity that may affect clear images of the retina.
  • 3. Subjects must not have had eye surgery in the past 2 months, be currently administering eye drops relating to previous eye surgery,
  • 4. Unable or unwilling to comply with the protocol requirements.

Ages Eligible for Study

to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

NeuroVision Imaging,

Shawn Kile, MD, PRINCIPAL_INVESTIGATOR, Sutter Health

Study Record Dates

2026-04